Patents by Inventor David Fedida
David Fedida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8207219Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: GrantFiled: January 19, 2010Date of Patent: June 26, 2012Assignee: Cardiome Pharma Corp.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M. R. Orth, Christian Hesketh
-
Publication number: 20120095073Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: May 18, 2011Publication date: April 19, 2012Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M.R. Orth
-
Publication number: 20100120890Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M. R. Orth, Christian Hesketh
-
Patent number: 7674820Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: GrantFiled: August 9, 2004Date of Patent: March 9, 2010Assignee: Cardiome Pharma Corp.Inventors: David Fedida, Gregory N Beatch, Alan M Ezrin, Peter M R Orth, Christian Hesketh
-
Publication number: 20090270478Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: March 20, 2009Publication date: October 29, 2009Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M.R. Orth
-
Patent number: 7507545Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: GrantFiled: August 9, 2004Date of Patent: March 24, 2009Assignee: Cardiome Pharma Corp.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter Orth
-
Publication number: 20090053721Abstract: The present invention provides novel methods and compositions for identifying ion channel modulating compounds, including atrial-selective antiarrhythmic agents and ion channel modulating compounds that preferentially modulate K+ channels. The ion channel modulating compounds identified according to these methods are associated with a reduced incidence of ventricular proarrhythmia.Type: ApplicationFiled: August 8, 2008Publication date: February 26, 2009Applicant: CARDIOME PHARMA CORP.Inventor: David Fedida
-
Publication number: 20060199848Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: September 7, 2006Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth
-
Publication number: 20060167226Abstract: The subject invention includes mutant voltage-gated ion channels that are open over a wide range of potential differences across membranes. The present invention also includes methods of use such mutant voltage-gated ion channels in cells with highly negative potential differences across their membranes. One preferred mutant voltage-gated ion channel is a channel with a mutation at the residue homologous to P513 in Kv1.5 and at least one mutation at one of the residues homologous to R400, R403, and R409 in Kv1.5.Type: ApplicationFiled: July 14, 2003Publication date: July 27, 2006Applicant: Cardiome Pharma Corp.Inventors: David Fedida, David Steele
-
Publication number: 20060135536Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: June 22, 2006Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth, Christian Hesketh
-
Publication number: 20050119315Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: June 2, 2005Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth
-
Publication number: 20050070552Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: August 9, 2004Publication date: March 31, 2005Applicant: Cardiome Pharma Corp.Inventors: David Fedida, Gregory Beatch, Alan Ezrin, Peter Orth, Christian Hesketh